Leidos to Form Security Screening Joint Venture With Medical Imaging Manufacturer

The intersection of defense prime contracting and medical device manufacturing is about to produce a rare corporate hybrid,one that exploits underpriced synergies between millimeter-wave imaging, computed tomography, and AI-driven threat detection. Leidos Holdings' decision to enter a joint venture structure with Analogic Corporation, a medical imaging OEM backed by private equity firm Altaris, represents more than typical industrial dealmaking. It signals a strategic bet that the Transportation Security Administration's next procurement cycle will favor integrated platforms capable of dual-use application across aviation security checkpoints and clinical diagnostic environments. The move also reflects Leidos' recognition that organic R&D timelines in advanced imaging cannot keep pace with accelerating TSA mandates for explosives detection and biometric verification.

Leidos, a $15.4 billion revenue defense and technology integrator as of fiscal 2024, has historically dominated the federal security screening infrastructure through its legacy Smiths Detection acquisition and subsequent TSA contract awards. Analogic, a Massachusetts-based manufacturer with roots in CT scanner subsystems and ultrasound technology, brings intellectual property in high-speed tomographic reconstruction algorithms and detector array miniaturization,capabilities directly applicable to next-generation checkpoint X-ray systems. The joint venture structure, rather than outright acquisition, suggests both parties seek to preserve capital efficiency while sharing regulatory risk and development costs. Altaris, a healthcare-focused buyout firm, acquired Analogic in 2018 for approximately $1.1 billion in a take-private transaction, positioning the company for strategic partnerships rather than standalone growth. Terms of the new venture were not disclosed, but the formation reflects a broader trend: defense primes are moving downstream into component manufacturing to capture margin and control technology roadmaps, while private equity-backed industrials seek liquidity events through strategic JVs rather than secondary sales.

An industry executive familiar with TSA procurement told Manufacturing Dive that the partnership aligns with the agency's shift toward multi-modal threat detection, where a single checkpoint scanner integrates explosive trace detection, 3D volumetric imaging, and biometric identity verification. "The question is whether Leidos can commercialize Analogic's medical-grade image processing fast enough to meet the 2027 TSA recapitalization timeline," the executive noted. The venture comes as global aviation passenger volumes are projected to exceed 10 billion annually by 2030, according to International Air Transport Association forecasts, intensifying demand for throughput-optimized screening infrastructure.

Why this matters beyond the defense industrial base: The JV structure creates a competitive moat that smaller pure-play security equipment vendors,FLIR Systems, OSI Systems, Smiths Group,will struggle to replicate. Medical imaging expertise is not easily acquired; it requires FDA regulatory knowledge, clinical trial infrastructure, and long-standing relationships with radiology OEMs like GE HealthCare and Siemens Healthineers. By partnering with Analogic, Leidos gains de facto access to FDA-validated component supply chains and detector technology that can be adapted for TSA certification at a fraction of the timeline and capital expense required for internal development. The implication: this is not a one-off deal but a template for how defense primes will consolidate adjacent technology verticals to maintain incumbency in multi-decade federal programs.

The Dual-Use Arbitrage: Why Medical Imaging IP Commands Premium Valuations in Security Markets

The core thesis animating this transaction is straightforward: computed tomography algorithms developed for oncology and cardiology applications can be re-engineered to detect low-density explosives and 3D-printed firearms with minimal incremental R&D. Analogic's legacy product portfolio includes CT scanner subsystems for Toshiba Medical (now Canon Medical Systems) and proprietary digital detector arrays used in baggage screening systems. These components share a common technical foundation,high-speed analog-to-digital conversion, real-time image reconstruction, and machine learning-based anomaly detection. The arbitrage opportunity lies in regulatory asymmetry: medical devices undergo years of clinical validation and FDA pre-market approval, creating a de facto barrier to entry that security equipment vendors cannot easily cross. Conversely, TSA certification for checkpoint scanners requires explosive detection benchmarks but lacks the longitudinal safety data mandates of medical devices. Leidos is betting that Analogic's medical pedigree will expedite TSA approvals while differentiating its product offering from commoditized X-ray vendors.

The economics are compelling. Medical imaging components command gross margins in the 40-50% range due to IP protection and regulatory barriers, while traditional security screening hardware operates at 25-30% margins in a competitive bid environment. By embedding Analogic's higher-margin subsystems into integrated security platforms, Leidos can defend pricing power in TSA contract renewals and international airport tenders. The JV structure allows both parties to share development risk while preserving balance sheet flexibility,critical for Altaris, which likely seeks a partial exit within the next 24-36 months. The private equity playbook here is textbook: acquire a distressed or subscale industrial asset, engineer operational improvements, then monetize through strategic partnerships rather than an outright sale that might attract antitrust scrutiny or undervalue the technology portfolio.

TSA Recapitalization and the $8 Billion Checkpoint Modernization Opportunity

The timing of this venture coincides with the TSA's accelerating timeline to replace legacy 2D X-ray systems with 3D computed tomography scanners across U.S. airports. As of early 2024, the agency had deployed approximately 500 CT units at checkpoint lanes nationwide, representing less than 10% of total screening infrastructure. The full buildout,estimated at 5,000+ units across 440 federalized airports,implies a procurement opportunity north of $8 billion over the next decade, assuming a blended unit cost of $1.5-1.8 million per CT scanner including installation and integration. Leidos already holds incumbent positions through its Security & Transportation segment, which generated $2.3 billion in revenue during fiscal 2024. The Analogic partnership strengthens its competitive positioning against Smiths Detection, Rapiscan Systems (a subsidiary of OSI Systems), and European entrants such as Nuctech.

Beyond the TSA domestic footprint, international markets present outsized growth potential. The European Union's aviation security regulations mandate CT-based explosive detection at all major airports by 2025, a deadline that has already slipped due to supply chain constraints and vendor certification delays. Middle Eastern aviation hubs,Dubai International, Hamad International in Doha, King Abdulaziz in Jeddah,are undergoing multi-billion-dollar terminal expansions that require state-of-the-art security infrastructure. Analogic's medical imaging export compliance and international manufacturing footprint give Leidos optionality to serve non-U.S. government customers without triggering International Traffic in Arms Regulations (ITAR) restrictions that constrain traditional defense exports. The strategic calculus is clear: this JV is as much about capturing international revenue streams as it is about defending domestic TSA incumbency.

The Altaris Exit Calculus: PE-Backed Industrials as Strategic JV Feedstock

From Altaris' perspective, the joint venture represents a textbook value-creation lever for private equity-backed healthcare industrials. The firm acquired Analogic in 2018 for approximately $1.1 billion, taking the company private after years of underperformance as a publicly traded entity. Since then, Altaris has rationalized Analogic's product portfolio, divested non-core ultrasound assets, and refocused the company on high-margin CT subsystems and detector technology. The Leidos partnership provides a monetization pathway that avoids the complexity and valuation risk of a full exit in a challenged IPO market. Rather than pursuing a secondary buyout or strategic sale,both of which would require navigating antitrust review and potentially accepting a distressed multiple,Altaris can crystallize value through a JV structure that preserves upside exposure while de-risking the portfolio company's growth trajectory.

This mirrors a broader trend in middle-market industrial private equity: rather than holding assets for the traditional 5-7 year fund lifecycle, sponsors are increasingly using strategic partnerships and minority recapitalizations to extend hold periods and capture secular growth in adjacent verticals. The healthcare-defense convergence thesis is particularly attractive because it allows PE firms to participate in federal procurement budgets,historically the domain of defense primes and large-cap government contractors,without the regulatory burden of prime contractor status. Altaris retains operational control and upside participation in the security screening market, while Leidos provides federal contracting infrastructure, TSA relationships, and integration expertise. The implicit bet: the value of Analogic's technology stack is higher when embedded in a defense platform than as a standalone medical device supplier.

Competitive Dynamics: Who Gets Squeezed in the Security Screening Stack

The formation of the Leidos-Analogic venture reshapes competitive dynamics across the security equipment value chain. Incumbent checkpoint scanner vendors,particularly Smiths Detection and Rapiscan,now face a strategic disadvantage: neither possesses in-house medical imaging IP or FDA-validated component supply chains. Smiths, a subsidiary of UK-based Smiths Group PLC, has historically relied on third-party CT detector suppliers and software licensors, limiting its ability to differentiate on image quality or throughput speed. Rapiscan, owned by California-based OSI Systems, operates a more vertically integrated model but lacks exposure to medical imaging end markets and the associated R&D scale. Both companies are now effectively competing against a combined entity that can amortize technology development costs across healthcare and security verticals, a structural cost advantage that will compress margins for smaller players.

The implications extend beyond checkpoint scanners. Leidos' move into medical imaging partnerships could catalyze similar deals across the defense industrial base. Lockheed Martin and Raytheon Technologies have both explored adjacencies in biodefense and pandemic preparedness, leveraging their systems integration capabilities to enter public health markets. If the Leidos-Analogic venture proves successful in capturing TSA share and achieving margin expansion, expect other defense primes to pursue similar healthcare industrial partnerships, particularly in areas where dual-use technology can be monetized across federal and commercial end markets. The strategic lesson: in an era of constrained defense budgets and mounting pressure to diversify revenue streams, defense contractors are increasingly willing to share equity and control in exchange for access to adjacent technology platforms and customer bases.

The Plocamium View

We interpret this joint venture as the opening salvo in a multi-year consolidation wave across the security screening and medical imaging intersection. The structural drivers are durable: aging TSA infrastructure, rising international aviation throughput, and accelerating regulatory mandates for 3D threat detection. But the strategic insight is more nuanced. Leidos is not merely acquiring technology,it is acquiring regulatory arbitrage. Analogic's FDA-validated component supply chains and medical imaging IP create a moat that pure-play security vendors cannot replicate without multi-year investment and clinical trial infrastructure. The JV structure allows both parties to share risk while preserving optionality, a hallmark of disciplined capital allocation in capital-intensive industrials.

The second-order play is private equity's evolving role as a strategic M&A intermediary. Altaris is effectively using Analogic as a platform to monetize defense sector demand for healthcare technology without the execution risk of a full exit or the valuation compression of a distressed sale. This is the future of middle-market industrial PE: rather than flipping assets to the next sponsor, firms are engineering strategic partnerships with large-cap corporates to create synthetic liquidity events while retaining upside exposure. Expect more healthcare industrials backed by PE to pursue similar JV structures with defense primes, particularly in areas where dual-use technology can be certified across both FDA and federal procurement channels.

The risk? Integration complexity and conflicting incentives. Leidos operates on multi-decade federal program timelines with predictable but low-growth revenue streams. Analogic, under Altaris ownership, is optimized for rapid value creation and near-term exit optionality. The tension between long-cycle defense contracting and PE-style value creation could undermine the venture's execution velocity, particularly if TSA procurement timelines slip or international market penetration proves slower than modeled. Our base case: the venture achieves modest TSA share gains but underperforms on international expansion due to export compliance friction and incumbent vendor relationships. The real winner is Altaris, which will use the JV as a springboard for a secondary monetization event within 24 months,either a strategic sale of its remaining Analogic stake or a minority recapitalization that values the company at a defense multiple rather than a medical device multiple.

The Bottom Line

The Leidos-Analogic joint venture is less about security screening innovation and more about regulatory arbitrage and vertical integration as competitive moats in federal contracting. Defense primes are moving downstream into component manufacturing to capture margin and control technology roadmaps, while private equity-backed industrials are using strategic partnerships to engineer synthetic exits in a challenging IPO environment. The playbook is clear: find dual-use technology platforms with FDA validation, partner with a defense prime for federal market access, and monetize the equity stake before integration complexity erodes value. For institutional investors, the signal is straightforward,consolidation in the security screening stack is accelerating, and the next 36 months will determine which vendors possess the scale and technology breadth to survive TSA recapitalization. The companies that cannot match Leidos' integrated offering will face margin compression and market share erosion. Position accordingly.